Live Webinar: HER2-Mutant NSCLC: Closing the Gap Between Detection and Optimal Treatment
Webinar/Online
Monday, January 26, 2026 at 5:00pm ET - 6:00pm ET
Add this event to your calendar
Info
Topic
Learn when and how to test for HER2 alterations in NSCLC; Get up to speed on the latest HER2-targeted therapies; Pick up practical tips to move faster from detection to the right treatment
Credits Offered
This event offers
1.0 CME credit
to attendees.
Accreditation Info:
i3 Health.
Additional Information
HER2 alterations are rare in NSCLC, but getting testing and treatment right is critical. Join this live, case-based webinar to learn when to test, explore new HER2-targeted therapies, & speed the path from detection to the right treatment.
Speakers
Associate Attending Physician
Thoracic Medical Oncologist
Memorial Sloan Kettering Cancer Center
Helena A. Yu, MD, is an Attending Physician and Thoracic Medical Oncologist at Memorial Sloan Kettering Cancer Center. She specializes in the treatment of lung cancer, and her research focuses on molecular testing and identifying mutations that can be used to develop targeted therapies and personalize lung cancer treatment. Dr. Yu oversees the clinical research program for EGFR-mutant lung cancers at Memorial Sloan Kettering and is an active investigator in clinical trials.
Attending Physician
Deputy Chief, Molecular Diagnostics Service
Department of Pathology and Laboratory Medicine
Memorial Sloan Kettering Cancer Center
Maria E. Arcila, MD, is an Attending Physician and the Deputy Chief of the Molecular Diagnostics Service in the Department of Pathology and Laboratory Medicine at Memorial Sloan Kettering Cancer Center. She specializes in molecular genetic pathology, and her research focuses on understanding the molecular changes behind the development of lung carcinoma and the identification of therapeutic and prognostic markers. Dr. Arcila is involved with numerous clinical trials investigating mutations and biomarkers in lung cancer.